Feel Comfortable Sticking With NovoSeven RT Over Sevenfact

December 2020

Sevenfact will join NovoSeven RT as another recombinant factor VIIa option to control bleeding in certain patients with hemophilia.

Sevenfact is currently approved to treat bleeds of any severity in patients 12 years and up with hemophilia A or B who develop “inhibitors”...antibodies to factor replacements.

Inhibitors can form against factor VIII (Advate, etc) or IX (BeneFix, etc) products...which limit their use to treat bleeding.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote